Desnervação renal no tratamento da hipertensão arterial resistente

morta, viva ou sobrevivendo?

Translated title of the contribution: Renal denervation in the treatment of resistant hypertension: Dead, alive or surviving?

Ahmad Al-Fakhouri, Nephertiti Efeovbokhan, Rami Nakhla, Rami Khouzam

Research output: Contribution to journalShort survey

Abstract

Hypertension is one of the most common chronic clinical problems encountered by physicians. The prevalence of resistant hypertension is estimated at 9% in the US. Patients with resistant hypertension have been shown to be at higher risk for adverse cardiovascular events, hence the need for greater efforts in improving the treatment of hypertension. The renal sympathetic nerves play an important role in the development of hypertension, mediated via sodium and water retention, increased renin release and alterations in renal blood flow. The proximity of the afferent and efferent renal sympathetic nerves to the adventitia of the renal arteries suggested the feasibility of an endovascular, selective, minimally invasive approach to renal denervation; a potential treatment option for resistant hypertension. While the RAPID, Reduce-HTN, EnligHTN, DENERHTN and Symplicity HTN-1 and -2 studies showed significant benefit of renal denervation in the treatment of resistant hypertension, the results of Oslo RDN, Prague-15 and Symplicity HTN-3 were not so favorable. Future well-designed clinical trials are needed to ascertain the benefits or otherwise of renal denervation in treatment-resistant hypertension.

Original languagePortuguese
Pages (from-to)531-538
Number of pages8
JournalRevista Portuguesa de Cardiologia
Volume35
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Denervation
Hypertension
Kidney
Therapeutics
Adventitia
Renal Circulation
Renal Artery
Renin
Sodium
Clinical Trials
Physicians
Water

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Desnervação renal no tratamento da hipertensão arterial resistente : morta, viva ou sobrevivendo? / Al-Fakhouri, Ahmad; Efeovbokhan, Nephertiti; Nakhla, Rami; Khouzam, Rami.

In: Revista Portuguesa de Cardiologia, Vol. 35, No. 10, 01.10.2016, p. 531-538.

Research output: Contribution to journalShort survey

Al-Fakhouri, Ahmad ; Efeovbokhan, Nephertiti ; Nakhla, Rami ; Khouzam, Rami. / Desnervação renal no tratamento da hipertensão arterial resistente : morta, viva ou sobrevivendo?. In: Revista Portuguesa de Cardiologia. 2016 ; Vol. 35, No. 10. pp. 531-538.
@article{d756b34932564daf89ed52524690d4e2,
title = "Desnerva{\cc}{\~a}o renal no tratamento da hipertens{\~a}o arterial resistente: morta, viva ou sobrevivendo?",
abstract = "Hypertension is one of the most common chronic clinical problems encountered by physicians. The prevalence of resistant hypertension is estimated at 9{\%} in the US. Patients with resistant hypertension have been shown to be at higher risk for adverse cardiovascular events, hence the need for greater efforts in improving the treatment of hypertension. The renal sympathetic nerves play an important role in the development of hypertension, mediated via sodium and water retention, increased renin release and alterations in renal blood flow. The proximity of the afferent and efferent renal sympathetic nerves to the adventitia of the renal arteries suggested the feasibility of an endovascular, selective, minimally invasive approach to renal denervation; a potential treatment option for resistant hypertension. While the RAPID, Reduce-HTN, EnligHTN, DENERHTN and Symplicity HTN-1 and -2 studies showed significant benefit of renal denervation in the treatment of resistant hypertension, the results of Oslo RDN, Prague-15 and Symplicity HTN-3 were not so favorable. Future well-designed clinical trials are needed to ascertain the benefits or otherwise of renal denervation in treatment-resistant hypertension.",
author = "Ahmad Al-Fakhouri and Nephertiti Efeovbokhan and Rami Nakhla and Rami Khouzam",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.repc.2016.06.005",
language = "Portuguese",
volume = "35",
pages = "531--538",
journal = "Revista Portuguesa de Cardiologia",
issn = "0870-2551",
publisher = "Sociedade Portuguesa De Cardiologia",
number = "10",

}

TY - JOUR

T1 - Desnervação renal no tratamento da hipertensão arterial resistente

T2 - morta, viva ou sobrevivendo?

AU - Al-Fakhouri, Ahmad

AU - Efeovbokhan, Nephertiti

AU - Nakhla, Rami

AU - Khouzam, Rami

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Hypertension is one of the most common chronic clinical problems encountered by physicians. The prevalence of resistant hypertension is estimated at 9% in the US. Patients with resistant hypertension have been shown to be at higher risk for adverse cardiovascular events, hence the need for greater efforts in improving the treatment of hypertension. The renal sympathetic nerves play an important role in the development of hypertension, mediated via sodium and water retention, increased renin release and alterations in renal blood flow. The proximity of the afferent and efferent renal sympathetic nerves to the adventitia of the renal arteries suggested the feasibility of an endovascular, selective, minimally invasive approach to renal denervation; a potential treatment option for resistant hypertension. While the RAPID, Reduce-HTN, EnligHTN, DENERHTN and Symplicity HTN-1 and -2 studies showed significant benefit of renal denervation in the treatment of resistant hypertension, the results of Oslo RDN, Prague-15 and Symplicity HTN-3 were not so favorable. Future well-designed clinical trials are needed to ascertain the benefits or otherwise of renal denervation in treatment-resistant hypertension.

AB - Hypertension is one of the most common chronic clinical problems encountered by physicians. The prevalence of resistant hypertension is estimated at 9% in the US. Patients with resistant hypertension have been shown to be at higher risk for adverse cardiovascular events, hence the need for greater efforts in improving the treatment of hypertension. The renal sympathetic nerves play an important role in the development of hypertension, mediated via sodium and water retention, increased renin release and alterations in renal blood flow. The proximity of the afferent and efferent renal sympathetic nerves to the adventitia of the renal arteries suggested the feasibility of an endovascular, selective, minimally invasive approach to renal denervation; a potential treatment option for resistant hypertension. While the RAPID, Reduce-HTN, EnligHTN, DENERHTN and Symplicity HTN-1 and -2 studies showed significant benefit of renal denervation in the treatment of resistant hypertension, the results of Oslo RDN, Prague-15 and Symplicity HTN-3 were not so favorable. Future well-designed clinical trials are needed to ascertain the benefits or otherwise of renal denervation in treatment-resistant hypertension.

UR - http://www.scopus.com/inward/record.url?scp=84991200742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991200742&partnerID=8YFLogxK

U2 - 10.1016/j.repc.2016.06.005

DO - 10.1016/j.repc.2016.06.005

M3 - Short survey

VL - 35

SP - 531

EP - 538

JO - Revista Portuguesa de Cardiologia

JF - Revista Portuguesa de Cardiologia

SN - 0870-2551

IS - 10

ER -